The efficacy of Herceptin therapies is influenced by the expression of other erbB receptors, their ligands and the activation of downstream signalling proteins
about
Phosphotyrosine interactome of the ErbB-receptor kinase familyLaminin isoform expression in breast tumors.Up-regulation of c-Jun-NH2-kinase pathway contributes to the induction of mitochondria-mediated apoptosis by alpha-tocopheryl succinate in human prostate cancer cells.Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancerProfiling the HER3/PI3K pathway in breast tumors using proximity-directed assays identifies correlations between protein complexes and phosphoproteins.Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping.A system for quantifying dynamic protein interactions defines a role for Herceptin in modulating ErbB2 interactions.A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancerInsulin-like growth factor-1 receptor signaling increases the invasive potential of human epidermal growth factor receptor 2-overexpressing breast cancer cells via Src-focal adhesion kinase and forkhead box protein M1.Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block.Role of IGF1R in Breast Cancer Subtypes, Stemness, and Lineage DifferentiationPharmacological strategies to overcome HER2 cross-talk and Trastuzumab resistance.The Therapeutic Challenge of Targeting HER2 in Endometrial CancerDeciphering the role of insulin-like growth factor-I receptor in trastuzumab resistance.Transphosphorylation of kinase-dead HER3 and breast cancer progression: a new standpoint or an old concept revisited?Inhibition of the HER2 pathway by n-3 polyunsaturated fatty acids prevents breast cancer in fat-1 transgenic mice.Dual targeting of ErbB-2/ErbB-3 results in enhanced antitumor activity in preclinical models of pancreatic cancer.Proteins Involved in HER2 Signalling Pathway, Their Relations and Influence on Metastasis-Free Survival in HER2-Positive Breast Cancer Patients Treated with Trastuzumab in Adjuvant SettingIGF1R Protein Expression Is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2+ Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831.Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro.HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors.Mapping normal and cancer cell signalling networks: towards single-cell proteomics.Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4-1 and NRDP1, in primary breast cancer
P2860
Q24672516-C8234F57-0774-43B9-B840-E33B53740405Q24810816-6C3DEB4B-7A94-46A6-B763-3C0F857406E8Q25255636-8FA0723B-1E6C-4105-86F0-4DAC063A2B7DQ28728701-B073B756-1E4A-4520-89D3-E1D02B79746BQ30997919-5E467B9C-B28F-4971-BB48-E27D35970E31Q34436356-5E14FDB4-4AD5-4439-823F-8FE534629C98Q34587922-096BC0BF-3B67-40DE-8A0E-EE054A1AD5F5Q34650878-3F818A01-62D0-428F-B440-E644D9BC43D4Q34946846-ED9C1557-4281-4769-8F2B-E8893B09B0A6Q34985562-6F0D4B6E-3320-488F-8E3A-E308C77A39A8Q35535296-CEAC118A-0F40-42D2-86EB-B8408B199D5FQ35803226-A2F4809E-0559-4D31-8558-3D139A8FFD21Q36064912-B1E9D19B-8E43-4117-A142-FD59E5614381Q36102124-C7382F85-CAE6-45D3-95F2-696B940FD70CQ36458755-007254B3-ABDF-4DF6-A21A-1452AB9FA974Q37305409-6225D912-79F1-4D60-903F-2DA86A018590Q37536346-11EC5650-25DB-46FD-A84A-9C21D986BC2CQ37604329-8BB1407B-0C2D-4BB4-85D5-2D92587B3047Q38770018-A485B8C2-6CDC-485F-B9C6-D0CFDF749ED0Q39931512-DB993E87-C9EF-4AF6-83E6-22C602CDBF83Q46003410-8BB67919-1C23-4BD2-AB49-BCD2E2F49F88Q46307051-69CC4532-E7BE-43E2-AF4B-CF0E72B4DED5Q58112887-E379A6C8-8875-409F-ADF1-19B786DDA0D7
P2860
The efficacy of Herceptin therapies is influenced by the expression of other erbB receptors, their ligands and the activation of downstream signalling proteins
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2004
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The efficacy of Herceptin ther ...... downstream signalling proteins
@en
The efficacy of Herceptin ther ...... ownstream signalling proteins.
@nl
type
label
The efficacy of Herceptin ther ...... downstream signalling proteins
@en
The efficacy of Herceptin ther ...... ownstream signalling proteins.
@nl
prefLabel
The efficacy of Herceptin ther ...... downstream signalling proteins
@en
The efficacy of Herceptin ther ...... ownstream signalling proteins.
@nl
P2093
P2860
P356
P1476
The efficacy of Herceptin ther ...... downstream signalling proteins
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BJC.6602090
P407
P577
2004-09-01T00:00:00Z